Navigation Links
Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
Date:8/10/2011

lease contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statem
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
2. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
3. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
4. Delcath on Preliminary List of Additions to Russell Microcap® Index
5. Delcath to Present at the JMP Securities Research Conference
6. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
7. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
8. Delcath to Update Investors on FDA Meeting
9. Delcath Expands Board of Directors With Appointment of Gabriel Leung
10. Delcath to Present at Upcoming Investor Conferences
11. Delcath Systems Receives Refusal to File Letter From FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...   MeridianRx earned highest possible score ... leading indicators during its recent URAC accreditation review ... very proud of earning this level of accreditation ... Operating Officer of MeridianRx. "It is a testament ... flexibility and innovation." URAC,s leading indicators ...
(Date:3/5/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... biosimilar therapeutics including high value and difficult to ... and full year 2014 financial results will be ... market opens for trading.  At 9:00 am Eastern ... to discuss the financial results and provide a ...
(Date:3/5/2015)... Texas , March 5, 2015 ... bio-analytical solutions company focused on gynecologic disease, announced ... financial results before the market open on Wednesday, ... call and webcast at 8:30am Eastern. Conference Call ... 2015 at 8:30am Eastern/5:30am Pacific Domestic: , 800-753-9057International: ...
Breaking Medicine Technology:MeridianRx Earns Highest URAC Accreditation Status 2Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2
... A78/Hall 10 -- Varian Medical Systems, Inc. (NYSE: ... new PaxPower™ X-ray tubes at the MEDICA 2011 International Trade ... The Varian booth will highlight: The PaxPower™ ... radiological imaging systems.  The tube uses Varian,s a rotating anode ...
... 2011 The grand opening ceremony for the world,s largest ... RNL BIO ( www.rnl.co.kr ), South Korea,s premier ... stem cell medical center in Beijing, China. Beijing RNL Stem ... Research Institute" (President : Li Hailing, www.yandaco.com ). Beijing ...
Cached Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors and X-ray Tubes at the MEDICA 2011 International Trade Fair 2RNL Opens the World's Largest Stem Cell Medical Center in Beijing, China 2
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Parents need ... fatal reality of substance use disorders. School programs like ... be marginally successful. NOPE, or Narcotics Overdose Prevention and ... according to Healthline News on Feb. 27th. ... and prescription opiate drugs, drug prevention proponents are lobbying ...
(Date:3/6/2015)... Anaheim, Cailfornia (PRWEB) March 06, 2015 ... lifestyle technology company, announced today the launch of ... save money on healthy and sustainable products at ... retailers. Makeena is exhibiting at Expo West Booth ... to search by gluten-free, Kosher, non-GMO, organic, Paleo, ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... new study challenges the widespread perception that bulimia primarily ... Blair Waldorf, who battled bulimia on the show earlier ... American are 50 percent more likely than girls who ... girls from families in the lowest income bracket studied ...
... Start of a Long-Term Trend in Infant HealthWHITE PLAINS, N.Y., ... in 2007 - a finding that the March of Dimes ... trend in improved maternal and infant health. The preterm birth ... preterm) and among babies born to African American and white ...
... Solutions and Patient Questionnaires for Clinical Trials announced that it has ... to collect data from patients at home on electronic diaries in ... ... AZ (PRWEB) March 18, 2009 -- assisTek, the Leader in ...
... 18 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... , the world,s first permanent tattoo ink designed to be ... alt.news 26.46 television segment shown on February 22, 2009 on ... and development of the ink as well as its use ...
... Suggests Parents Most Influence Teens, Decisions About SexWASHINGTON, March 18 ... 1% in 2007, according to data released today by the ... second year in a row that the teen birth rate ... decline in the teen birth rate. That is, after ...
... that the PSA test is a far from perfect tool ... offer conflicting views on the value of screening men with ... , But at least one leading oncologist says this much ... family history of prostate cancer should pay attention to a ...
Cached Medicine News:Health News:Black girls are 50 percent more likely to be bulimic than white girls 2Health News:Black girls are 50 percent more likely to be bulimic than white girls 3Health News:Preterm Birth Rate Drops 2Health News:Preterm Birth Rate Drops 3Health News:Preterm Birth Rate Drops 4Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 2Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 3Health News:Nuvilex' Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program 2Health News:Teen Birth Rate Up For Second Year in a Row 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 3
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... Spectrophotometers are simple, reliable ... use in many types ... clinical, industrial and environmental ... vial holders, Windows based ...
Spectra 5000 is one of the most versatile analytical devices used in conventional laboratories which can work in the ultravoilet and visible range from 200 to 1000 nm for quantitative and qualitative...
... 400 Series Spectrophotometer ... approach to UV-VIS instrumentation. ... are incorporated into a ... in features and performance ...
Medicine Products: